Last reviewed · How we verify
SB-AS02B adjuvant
SB-AS02B adjuvant is a Biologic drug developed by SWOG Cancer Research Network. It is currently in Phase 2 development.
SB-AS02B adjuvant is an incomplete Freund's adjuvant, also known as Montanide ISA 51 VG, used in combination with the D1/3-MAGE-3-His fusion protein in a clinical trial for melanoma (skin) treatment. The exact mechanism of SB-AS02B adjuvant is unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SB-AS02B adjuvant |
|---|---|
| Sponsor | SWOG Cancer Research Network |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery (PHASE2)
- Vaccine Therapy in Treating Patients With Stage IV Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-AS02B adjuvant CI brief — competitive landscape report
- SB-AS02B adjuvant updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI
Frequently asked questions about SB-AS02B adjuvant
What is SB-AS02B adjuvant?
Who makes SB-AS02B adjuvant?
What development phase is SB-AS02B adjuvant in?
Related
- Manufacturer: SWOG Cancer Research Network — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing